Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The Сompany also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its prodcuts, include Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

Show more
Type
Public
HQ
Indianapolis, US
Founded
1876
Size (employees)
41,975 (est)
Website
lilly.com
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Report incorrect company information

Key People/Management at Eli Lilly

David Ricks

David Ricks

Chairman and Chief Executive Officer
Melissa Barnes

Melissa Barnes

Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique Conterno

Enrique Conterno

Senior Vice President and President, Lilly Diabetes and Lilly USA
Stephen Fry

Stephen Fry

Senior Vice President, Human Resources and Diversity
Michael Harrington

Michael Harrington

Senior Vice President and General Counsel
Susan Mahony

Susan Mahony

Senior Vice President and President, Lilly Oncology
Show more

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 141 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Toronto, CA
3650 Danforth Ave
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham, GB
Erl Wood Manor Sunninghill Road
Show all (196)
Report incorrect company information

Eli Lilly Financials and Metrics

Eli Lilly Financials

Eli Lilly's revenue was reported to be $21.22 b in FY, 2016 which is a 6.3% increase from the previous period.
USD

Revenue (Q1, 2018)

5.7 b

Market capitalization (14-Jun-2018)

93.7 b

Closing share price (14-Jun-2018)

86.4
Eli Lilly's current market capitalization is $93.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1 b19.6 b20 b21.2 b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b
Quarterly
USDQ1, 2018

Revenue

5.7 b

Pre tax profit

1.4 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m

Inventories

2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b
Quarterly
USDQ1, 2018

Current Liabilities

11.5 b

Additional Paid-in Capital

5.8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
AurKa Pharma May 15, 2018$575 m
ARMO BioSciences Inc May 11, 2018$1.60 b
CoLucid Pharmaceuticals January 18, 2017$960 m
Novartis Animal Health April 22, 2014$5.40 b
Avid Radiopharmaceuticals November 08, 2010$800 m
Alnara Pharmaceuticals July 02, 2010$280 m
Imclone Systems October 06, 2008$6.50 b
Report incorrect company information

Eli Lilly Online and Social Media Presence

Embed Graph
Report incorrect company information

Eli Lilly News and Updates

Eli Lilly, AstraZeneca’s Alzheimer’s Drug Flop Is the Latest Disappointment in a Frustrating Disease

The story of Alzheimer's drug development is one of perpetual tragedy and setbacks.

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics--Novartis' Cosentyx, Eli Lilly's Taltz, and Janssen's Tremfya

EXTON, Pa., June 12, 2018 /PRNewswire/ -- Spherix Global Insights' second quarter update of RealTime Dynamix™: Psoriasis (US) reveals significant changes afoot in the current psoriasis biologic landscape.  Year-over-year analysis indicates continued erosion of the established agents, such...
Show more
Report incorrect company information